The abstracts of the LATITUDE trial and the comparable arm of the STAMPEDE trial, in which patients with newly diagnosed, metastatic prostate cancer were randomized to either ADT or ADT + abiraterone acetate + prednisone were both released this morning. Both trials have shown major benefits to the early addition of abiraterone acetate to standard care. We shall be providing more details in separate reports to come later today.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: abiraterone, metastatic, survival |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply